The Mrp2 mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute. The model was created through targeting of the Abcc2 gene in 129/Ola-derived E14 ES cells and injecting the targeted cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to FVB/N for seven generations (N7). Taconic received stock in 2006, and the line was embryo transfer derived. The colony is maintained by mating homozygotes.
Wild type for Nnt mutation; carries Pde6brd1 mutation
Vlaming MLH, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RPJ, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JHM, Schinkel AH. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318(1):319-327
van Waterschoot RAB, ter Heine R, Waagenar E, van der Kruijssen CMM, Rooswinkel RW, Huitema ADR, Beijnen JH, Schinkel AH (2010). Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160(5):1224-1233.